益气化毒方联合膀胱灌注化疗对浅表性膀胱癌术后患者生存质量及免疫功能的影响

The effect of Yiqi Huadu decoction combined with bladder perfusion chemotherapy on superficial bladder cancer postoperative patients life quality and immune function

目的 探讨益气化毒方联合膀胱灌注化疗对浅表性膀胱癌术后患者生存质量及免疫功能的影响.方法 按照连续入组的方式选择120例浅表性膀胱癌术后患者,按照数字列表法随机分为观察组与对照组各60例,对照组给予盐酸吡柔比星30mg/次膀胱灌注化疗,1次/周,连用8周,以后1次/月,连续治疗12个月;观察组在盐酸吡柔比星膀胱灌注化疗的基础上,术后l周给予益气化毒方口服治疗,1剂/d,连用3个月,以后1剂/2d,连续治疗12个月,比较两组患者术后12个月后生存质量量表（SF-36）评分及免疫功能指标.结果 ①观察组治疗12个月后SF-36量表总体健康、生理职能、生理功能、躯体疼痛、社会功能、活力、情感职能及精神健康8个维度及总分明显高于对照组,比较差异有统计学意义（P＜0.05）;②治疗12个月观察组IgG、IgA、IgM水平,CD3、CD4百分比较对照组增高显著,CD8百分比与CD4/CD8比值降低显著,两组比较差异有统计学意义（P＜0.05）;③观察组不良反应发生率为6.67％,明显低于对照组的18.33％,比较差异有统计学意义（P＜0.05）.结论 益气化毒方联合膀胱灌注化疗有助于提高浅表性膀胱癌术后患者的生存质量,改善免疫功能,且具有较高安全性。

Objectives To study the effect of Yiqi Huadu decoction combined with bladder perfusion chemotherapy on superficial bladder cancer postoperative patients life quality and immune function.Methods 120 cases of patients with superficial bladder cancer after surgery were selected according to a continuous way,In accordance with the list of numbers were randomly divided into the observation group and the control group with 60 cases in each group,and the control group was given pirarubicin intravesical instillation of 30mg/time,1 times / week,for 8 weeks,after the 1 / month,the 12 months of consecutive treatment;However,the observation group was based on pirarubicin i ntravesical chemotherapy,and after 1 weeks given Yiqi Huadu decoction of oral treatment for 1 dose/d,for 3 months,after the 1 dose of/2d,continuous treatment for 12 months,there were compared that the quality of Life Scale（SF-36） scores and immune function parameters between the two groups of patients after 12 months after.Results ①The observation group after 12 months of treatment SF-36 scale,general health,physical function,physical function,bodily pain,vitality,social function,emotional function and mental health of 8 dimensions and total score were significantly higher than the control group,so the difference was statistically significant（P 〈0.05）;②The treatment of 12 months in the observation group＇s IgA,IgM levels,CD3,CD4 percentage were significantly higher than the control group,but CD8 percentage of CD4/CD8 ratio significantly decreased,there was significant difference between two groups（P 〈 0.05）;③ The adverse reaction rate of the observation group was 6.67% which was significantly lower than the control group＇s 18.33%,7so the difference was statistically significant（P 〈0.05）.Conclusions It＇s application will has a higher security for to help to improveimproving the quality of life and improve improving immune function of patients with superficial bladder cancer that Yiqi Huadu decoction combined with bladder perfusion chemotherapy.